<DOC>
	<DOCNO>NCT01074320</DOCNO>
	<brief_summary>Current guideline recommend endocrine treatment aromatase inhibitor ( AIs ) post-menopausal woman hormone receptor-positive breast cancer . Musculoskeletal symptoms commonly report AI treatment , however , consistent method measure symptoms prospectively . This gap knowledge inhibit ability test develop treatment AI-associated musculoskeletal symptom . This pilot study evaluate functional test standardize instrument ability prospectively assess musculoskeletal symptom woman treat AIs breast cancer .</brief_summary>
	<brief_title>Measuring Musculoskeletal Symptoms Patients Receiving Aromatase Inhibitors</brief_title>
	<detailed_description>Specific Aims : 1 ) identify core set instrument measure musculoskeletal symptom , 2 ) model time course predictor change musculoskeletal symptom , 3 ) explore effect musculoskeletal symptom adherence AIs woman first 6 month AI treatment . Methods : We prospectively assess musculoskeletal symptom due treatment aromatase inhibitor . Post-menopausal woman begin AI treatment hormone responsive breast cancer invite join study .</detailed_description>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women stage I IIIa invasive breast cancer , Hormonereceptor positive cancer ( either ER+ PR+ ) , Prescribed agree take exemestane , anastrazole letrozole , Have complete initial treatment surgery , RT , and/or chemotherapy , Are postmenopausal , No previous history aromatase inhibitor therapy invasive breast cancer , Have sign consent form . History rheumatoid arthritis , Unable read understand English , History psychiatric disability affect informed consent compliance study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>musculoskeletal symptom</keyword>
</DOC>